Drug Trial Radar · NCT07938632
TL-925 for the Treatment of Allergic Conjunctivitis
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 100 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Conditions
- Allergic Conjunctivitis of Both Eyes
Interventions
TL-925Drug
TL-925 is an eye drop.
PlaceboDrug
The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Itching ScoreTime frame: Day 2, Day 16 and Day 23
- Conjunctival Redness ScoreTime frame: Day 2, Day 16 and Day 23
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Andover Eye Associates
Andover, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.